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Abstract: Obesity mediates most of its direct medical sequelae through the development of insulin
resistance (IR). The cellular effects of insulin occur through two main postreceptor pathways that
are the phosphatidylinositol 3-kinase (PI3-K) and the mitogen-activated protein kinase (MAP-K)
pathways. Obesity-related IR implicates the PI3-K pathway that confers the metabolic effects of
insulin. Numerous and complex pathogenic pathways link obesity with the development of IR, in-
cluding chronic inflammation, mitochondrial dysfunction (with the associated production of reactive
oxygen species and endoplasmic reticulum stress), gut microbiota dysbiosis and adipose extracellular
matrix remodelling. IR itself plays a key role in the development of metabolic dysfunction, including
hypertension, dyslipidaemia and dysglycaemia. Furthermore, IR promotes weight gain related to
secondary hyperinsulinaemia, with a resulting vicious cycle of worsening IR and its metabolic seque-
lae. Ultimately, IR underlies obesity-related conditions such as type 2 diabetes mellitus (T2D) and
polycystic ovary syndrome (PCOS). IR also underlies many obesity-related malignancies, through the
effects of compensatory hyperinsulinaemia on the relatively intact MAP-K insulin pathway, which
controls cellular growth processes and mitoses. Furthermore, the emergent data over recent decades
support an important role of obesity- and T2D-related central IR in the development of cognitive
dysfunction, including effects on hippocampal synaptic plasticity. Importantly, IR is largely reversible
through the optimisation of lifestyle factors that include regular engagement in physical activity with
the avoidance of sedentariness, improved diet including increased fibre intake and sleep sufficiency.
IR lies at the key crossroad between obesity and both metabolic and cognitive dysfunction. Given
the importance of IR in the pathogenesis of many 21st century chronic diseases and its eminent
reversibility, it is important that we all embrace and facilitate optimised lifestyles to improve the
future health and wellbeing of the populace.
Keywords: insulin resistance; obesity; metabolic dysfunction; cognitive dysfunction
1. Introduction
The global obesity epidemic has developed over the last half century [1]. Obesity
underlies many 21st century chronic diseases and confers a substantial socio-economic
burden globally, including contributing towards a large proportion of overall healthcare
costs [1]. Obesity affects people of any age, class, ethnicity or socio-economic group, with a
current prevalence in the UK of one in four adults [1].
Weight gain and obesity mediates most of its direct medical sequelae through wors-
ening insulin sensitivity and, as such, the development of insulin resistance (IR) [2]. In
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addition to malignancies such as endometrial carcinoma [1,3], IR underlies the cardio-
metabolic dysfunction that associates with obesity. This includes type 2 diabetes mellitus
(T2D) [1], polycystic ovary syndrome (PCOS) [4,5] and hypertension [6]. Furthermore,
such obesity-related IR is compounded by the development of other obesity-related condi-
tions such as obstructive sleep apnoea (OSA) [7] and male obesity-associated secondary
hypogonadism (MOSH) [8]. As such, IR lies at a key junction that is itself influenced by
multiple and complex pathways but also instigates multiple and complex downstream
effects that ultimately manifest with metabolic and cognitive dysfunction.
In this concise review (summarised in Figure 1), we explore the role of weight gain
with excess adiposity and obesity in the development of IR and the effects of IR on the
subsequent development of both metabolic and cognitive dysfunction. We also consider the
reversibility of IR through the effective implementation of lifestyle improvement strategies
including optimisation of physical activity, diet and sleep. Although inherent challenges
limit the successful longer-term maintenance of body weight following initial weight
loss [9,10], successful adoption of a healthy lifestyle regarding these key lifestyle factors
(regardless of the magnitude of weight loss) provides a sensible and feasible means of
improving insulin sensitivity and the overall health and wellbeing of the populace.
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Figure 1. Overview of the mechanisms that underlie obesity-related insulin resistance (IR) and the metabolic and cogni-
tive sequelae of IR. BBB: blood brain barrier; ECM: extracellular matrix; ER: endoplasmic reticulum; MAPK: mito-
gen-activated protein kinase; PI3K: phosphotidylinositol 3-kinase. Solid arrows: causative factors; speckled grey arrow: 
inhibitory factors. 
2. Role of Obesity in the Development of IR 
The clinical definition of IR is the inability of a known quantity of insulin (either 
endogenous or exogenous) to increase the uptake and utilisation of glucose in an indi-
vidual by the same degree as that in a normal population [11]. Insulin binds to its plasma 
membrane receptor and mediates its cellular effects through a series of protein–protein 
interactions [11]. There are two main postreceptor cellular pathways implicated: (i) the 
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2. Role of Obesity in the Development of IR
The clinical definition of IR is the inability of a known quantity of insulin (either
endogenous or exog nous) to increase t uptake and utilisatio of glucose in an individual
by the same degree as that in a normal population [11]. Insulin binds to its plasma
membrane receptor and mediates its cellular effects through a series of protein–protein
int ractions [11]. There are two main postreceptor cellular pathways implicated: (i) the
phosphatidylinositol 3-kinase (PI3-K) pathway and (ii) the mitogen-activated protein kinase
(MAP-K) pathway [12,13]. Each of these pathways confers different cellular functions of
insulin. The PI3-K pathway regulates cellular intermediary metabolism, whereas the
MAP-K pathway controls growth processes and mitoses [11]. Importantly, obesity-related
IR appears to affect predominantly and commensurately the PI3-K pathway, with the
MAP-K pathway remaining relatively unaffected [11–14]. Therefore, a more descriptive
definition of IR is perhaps “metabolic insulin resistance” [14]. The relative sparing of the
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MAP-K insulin pathway in obesity-related IR may help to explain the known association
between obesity and malignancy and promotes IR and the harmful effects of compensatory
hyperinsulinaemia as central to the pathogenesis of such tumours [15].
Given the close link between obesity and the development of PI3-K dysfunctional
IR, it is important to explore how obesity mediates its effects on the insulin pathway. It
seems likely that multiple and complex pathways are implicated, with inter-linking and
multidirectional effects. It is beyond the scope of this concise review to provide a detailed
exposition of the complexities of molecular mechanisms. Rather, we provide an overview
of the current main theories that link obesity with IR.
Chronic inflammation: The close association between body weight and IR [12,16]
is likely mediated, at least in part, through inflammatory pathways [17]. Weight gain
and obesity causes changes in the release of key adipokines and cytokines from adipose
tissue that in turn manifest in both paracrine and endocrine effects, with the latter from
release into the plasma. These changes include increased release of leptin and plasmino-
gen activator inhibitor-1 and reduced release of adiponectin [18]. These key changes
result in a generalised low-grade inflammatory response, mediated through infiltration of
macrophages and other immune cells into metabolic organs, such as white adipose tissue
(WAT), skeletal muscle, liver and pancreas [19]. This process associates with a shift from a
predominantly anti-inflammatory to a proinflammatory profile [20]. Macrophage release
of proinflammatory cytokines (including interleukin-1β that activates the “NOD-, LRR-
and pyrin domain-containing protein 3” (NLRP3) inflammasome) result in autocrine and
paracrine effects that enhance IR [20]. This chronic low-grade inflammatory response also
facilitates tumour cell motility and invasion [18].
Mitochondrial dysfunction: Obesity can overwhelm the capacity of eutopic WAT
depots. In this scenario, lipid deposition occurs ectopically in nonadipose tissues, such as
skeletal muscle and liver. In recent years, a great deal of evidence supports an important
role of mitochondrial dysfunction in the development of obesity-related IR, stimulated
through ectopic fat deposition [21]. Lipid-induced production of reactive oxygen species
(ROS) within skeletal muscle promotes mitochondrial dysfunction and the development of
IR [21]. Furthermore, a harmful feedback loop can occur whereby ROS production from
impaired mitochondria results in further mitochondrial dysfunction and the worsening of
IR [21]. Related to the mitochondrial dysfunction and production of ROS, obesity-induced
endoplasmic reticulum (ER) stress and inflammation within the liver may also result in
hepatic IR and gluconeogenesis [22].
Gut microbiota dysbiosis: In recent years, there has been a transformation in our
understanding of the gut microbiota and its role in health and chronic disease. A number of
our data originate from rodent models. In a recent meta-analysis of data on changes in the
gut microbiota in high-fat diet (HFD)-induced obese rodents, there was a demonstration of
the structural and functional dysbiosis of the gut microbiota in HFD-induced obesity [23].
Compared with their lean counterparts, HFD-induced obese rodents increased Lactococcus
and reduced Turicibacter, each consistent with an enhanced inflammatory response [23].
There was also an abundance of Dorea, Oscillospira and Ruminococcus. Furthermore,
functional differences in the gut microbiota between lean and HFD-induced obese rodents
occurred, with the latter manifesting metabolic pathways that converge on the biosynthe-
sis of lipid and carbohydrate and short chain fatty acid (SCFA) metabolism [23]. From
these data, it is not possible to implicate clearly gut microbiota dysbiosis as a mediator
between obesity and IR. The gut microbiota has multiple and complex effects on appetite
and metabolism and may influence body weight. Furthermore, we should be cautious
about extrapolating data from rodent studies into humans. However, the rodent data
outlined here provide compelling evidence that HFD-induced obesity associates with both
structural and functional gut microbiota dysbiosis, consistent with the promotion of a
proinflammatory state and the subsequent development of IR.
Adipose extracellular matrix (ECM) remodelling: In response to nutritional cues,
adipocytes and their precursors need to change their shape, size and function. This process
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requires remodelling within a WAT ECM [24]. Weight gain, with its associated expansion
of WAT depots, results in a localised hypoxic response: the expanded WAT essentially
outstrips its own vascular supply and becomes hypoxic, resulting in the acceleration of
fibrosis and inflammation within the expanding WAT [24]. In this scenario, the excessive
deposition of ECM within WAT limits the angiogenic response. Given the regulation of
insulin sensitivity by ECM receptors, such as CD44 and integrins, the accumulation of
ECM within the WAT results in the worsening of IR [24].
In addition to the mechanisms outlined above, numerous other factors influence
insulin sensitivity, some of which may be influenced in some way indirectly by weight
gain (excess adiposity) and obesity. Amongst these factors include genetic abnormalities
that affect the insulin receptor or the proteins of the cellular insulin pathway and fetal
malnutrition [11]. Vitamin D may also influence IR and has received a great deal of attention
in recent years. In one study on more than 2200 Greek schoolchildren aged between 9 and
13 years, the prevalence of the vitamin D insufficiency was significantly greater in children
with obesity compared with in their overweight and normal weight counterparts (60.5% vs.
51.6%) [25]. Furthermore, children with IR had a 1.48-fold greater likelihood of vitamin
D insufficiency compared with those without IR [25]. This study, as with much of the
literature on the influence of vitamin D on IR, reported on the association data in which the
proof of causality is lacking. Future studies should explore potential causal mechanisms
linking vitamin D insufficiency with IR, and the degree to which obesity mediates the
development of IR through effects on vitamin D. Possible indirect mechanisms include
reduced sunlight exposure of the skin or increased sequestration of vitamin D within WAT
with consequent reduced levels in the plasma.
To conclude this section, obesity-related IR appears confined to the PI3-K postreceptor
insulin pathway that regulates the cellular metabolic effects of insulin. Obesity contributes
towards the development of IR through numerous and complex mechanisms, which impli-
cate changes in adipokines, cytokines, inflammatory response, mitochondrial dysfunction,
ROS production, ER stress, gut microbial dysbiosis and remodelling of adipose ECMs.
From this perspective, IR is located at a crossroad or gateway that functions as a key
expedient linking weight gain and obesity with its metabolic and cognitive sequelae.
3. Role of IR in the Development of Metabolic Dysfunction
IR manifests with a reduction in the uptake and oxidation of glucose and reductions
in glycogen synthesis and the ability to suppress lipid oxidation [26]. Through the impair-
ment of the PI3-K insulin pathway, IR plays a key role in the development of metabolic
dysfunction and underlies a cluster of cardiovascular and metabolic abnormalities referred
to as the metabolic syndrome (including hypertension, dyslipidaemia and dysglycaemia).
Furthermore, IR promotes weight gain related to secondary compensatory hyperinsuli-
naemia [27], with a resulting vicious cycle of worsening IR and its metabolic sequelae.
Having explored the complex pathways that mediate effects of obesity on the development
of IR, in this section, we provide an overview of the mechanisms by which IR contributes
towards metabolic dysfunction.
Hypertension: IR results in compensatory hyperinsulinaemia that in turn may in-
crease blood pressure via multiple mechanisms. These include enhanced renal sodium
reabsorption, the hypertrophy of resistance blood vessels and the activation of the sym-
pathetic nervous system [28,29]. The development of hypertension can also result in
the worsening of IR through changes in the structure of the vasculature and the impair-
ment of vasodilation within skeletal muscle, with the reduced delivery of glucose and
insulin to skeletal muscle cells [28]. Interestingly, however, studies of animal models
of hypertension suggest that IR actually precedes the onset of hypertension, consistent
with a causal role of IR in the development of hypertension [30]. Furthermore, the data
from healthy human volunteers suggest that changes in autonomic regulation influence
insulin sensitivity. Autonomic imbalance may, therefore, result in both IR and hyperten-
sion, through effects on vasoconstriction [30]. Therefore, although there are close links
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between IR and hypertension, pathogenic mechanisms appear complex and incompletely
understood. Further studies are required to provide clarity regarding the exact underlying
pathophysiologic mechanisms.
Dyslipidaemia: IR results in enhanced hepatic flux of fatty acids originating from
the diet and resistance to the antilipolytic effects of insulin within adipose tissue [31].
These alterations of lipid metabolism manifest with dyslipidaemia and a characteristic
proatherogenic lipid triad consisting of high plasma levels of triglycerides, small and dense
low-density lipoproteins and low plasma levels of high-density lipoproteins [32]. Further-
more, such IR-induced aberrations of lipid profile may contribute towards inflammatory
responses within the endothelium.
Dysglycaemia: IR associates with imbalanced glucose metabolism and chronic hyper-
glycaemia that in turn can trigger oxidative stress and an inflammatory response [33]. The
reduced peripheral uptake of glucose into skeletal muscle cells represents a cardinal feature
of IR. In this context, compensatory hyperinsulinaemia due to the enhanced insulin release
from pancreatic β-cells helps to mitigate the development of hyperglycaemia. Therefore,
the development of T2D requires additionally a degree of pancreatic β-cell dysfunction [34].
Interestingly, the data from both physiological and epidemiological studies suggest that
disordered insulin secretion from pancreatic β-cells may actually contribute towards the
development of IR and subsequent T2D [34].
The metabolic consequences of IR outlined in this section often co-exist and together
contribute towards endothelial dysfunction and, ultimately, the formation of atherosclerotic
plaque. These pathogenic processes can eventually manifest with macrovascular events. In
the case of the myocardium, IR also causes damage through multiple pathways that include
altered delivery of substrates including free fatty acids [35], impaired regulation of substrate
metabolism [36] and alteration of signal transduction [37]. Furthermore, IR as a primary
pathogenic factor also underlies nonalcoholic fatty liver disease (NAFLD) [11]. Finally, IR
likely plays a key role in complex pathogenesis that underlies PCOS through metabolic
dysfunction that stems from selective IR within the PI3-K postreceptor insulin pathway [38]
and deleterious effects of compensatory hyperinsulinaemia on ovarian function (account-
ing for both hyperandrogenic and reproductive manifestations from co-gonadotrophin
steroidogenic [39] and preantral follicular arrest [40], respectively) [41–43].
4. Role of IR in the Development of Cognitive Dysfunction
Numerous factors influence cognitive function, including those of both genetic and en-
vironmental origin. As outlined earlier, obesity-associated IR associates with a generalised
chronic low-grade inflammatory response. Unfortunately, the brain is not immune from
such inflammatory effects that may ultimately increase the progression of cognitive decline
and the risk of development of Alzheimer’s disease (AD) [44]. In normal physiology, the
mediation of immune functioning within the brain occurs through microglial cells that
facilitate neuroprotection. However, in the context of central inflammation associated
with obesity and IR, these same microglial cells can transform into reactive microglia and
become injurious to local neuronal tissue (including apoptotic effects), through the release
of cytotoxic cytokines [45]. Other factors that influence cognitive function include the ex-
pression of polymorphic proteins within the brain, including most notably the expression
of ApoE4, as a risk factor for the development of dementia and cognitive impairment in
the elderly [46,47]. However, the data reported in the last few decades also promote the
central insulin pathway as an important determinant of cognitive function.
Insulin was first identified in the brain in 1978 [48]. Since then, a plethora of studies
have transformed our knowledge and understanding of centrally acting insulin. As in the
periphery, central insulin acts through the insulin receptor (IRec), but with predominant
effects on insulin-sensitive glucose transporters-1 and -3 (GLUT1 and GLUT3, respectively),
rather than GLUT4 which is the glucose transporter found primarily in adipose tissue
and skeletal muscle [49,50]. The distribution of IRecs (and co-localized insulin receptor
substrate (IRS)) [51] within the brain provides insight into insulin function centrally [52].
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Although IRec mRNA is located in neuronal cell bodies, the distribution of IRec recep-
tor protein is heterogeneous and includes pyramidal cell axons, neuronal terminals and
synapses [46,53–55]. Accordingly, the central expression of IRecs covers a wide distribution
including neuronal and glial cell expression, especially within areas important for cogni-
tion such as the cerebral cortex, hippocampus, hypothalamus and olfactory bulb [46,56].
Interestingly, the density of central IRecs differs between embryonic and adult brains [57].
Insulin within the brain, originating from the pancreatic β-cells and reliant upon
efficient IRec-mediated transport of insulin across the blood brain barrier (BBB) [58], plays
an important role in cognition, including the facilitation of learning and memory in older
people [59]. Underlying mechanisms that mediate the procognitive effects of insulin in-
clude the promotion of nerve cell growth and development as well as the regulation of
neurotransmitter release [59,60]. Furthermore, insulin provides nutritional support to nerve
cells [61] and regulates the expression of various enzymes implicated in the control of glu-
cose metabolism, including choline acetyltransferase [53]. Insulin may also support higher
brain functions such as learning and memory, through effects on hippocampal synaptic
plasticity [62]. The support for this hypothesis stems from a rat model of T1D (induced by
streptozotocin), in which both hippocampal synaptic plasticity and spatial memory ability
are significantly impaired and corrected by the administration of insulin [63]. Although
the mechanisms that underlie the links between central insulin signalling and synaptic
plasticity remain incompletely understood, this may implicate the modulation of gluta-
matergic neurotransmission [64] and the stimulation of translocation of γ-aminobutyric
acid (GABA) receptors to the plasma membrane, thereby increasing functional GABA
receptor expression within the postsynaptic membrane [46,65].
Following this outline of the important role of central insulin in the support and facili-
tation of cognitive function, it is important to consider the effects of IR on cognition. Any
impairment of the central insulin-signalling pathway appears to promote the advancement
of cognitive dysfunction [66]. Indeed, the existing evidence suggests that IR is an indepen-
dent risk factor for cognitive impairment and neurodegeneration [67]. This is consistent
with a known epidemiological and biological link between T2D and AD [67]. The incidence
of AD in patients with longstanding diabetes mellitus (DM) is twice that of normal elderly
people [68]. Furthermore, disturbed brain insulin signalling mechanisms contribute to-
wards the development of biochemical, molecular and histopathological lesions in patients
with AD [46,67,69].
The underlying mechanisms that mediate cognitive decline in the context of IR are
probably multifactorial. Central insulin signalling appears to depend on both the sensitivity
of central IRecs and adequate levels of insulin within the brain. In the early stages of IR,
secondary hyperinsulinaemia can result in the neuronal degeneration and irreversible
impairment of memory through the chronic exposure of neurons to elevated levels of
insulin within the brain [70]. However, over time, secondary hyperinsulinaemia can result
in damage to the function of the BBB, with the subsequently reduced transport of insulin
from the peripheral circulation into the brain parenchyma [71]. Indeed, in patients with AD,
there are usually low levels of insulin within the brain and cerebrospinal fluid (CSF), with
high levels of peripheral insulin [46,72]. Therefore, following initial neuronal impairment
from the effects of central hyperinsulinaemia, there is a reduction in the levels of central
insulin, despite peripheral hyperinsulinaemia. This scenario, compounded by central IR,
often associates with increased levels of cerebral beta amyloid that further worsens central
IR [73]. Finally, central IR also promotes tau protein phosphorylation [74] that contributes to
the formation of neurofibrillary tangles that in turn contributes towards impaired cognition
and ultimately AD pathology [46,75]. The combination of neuronal damage from early
exposure to chronic elevations of central insulin, impaired BBB function and subsequent
reduction in central insulin and central IR compounded by cerebral beta amyloid and tau
protein phosphorylation creates a perfect storm for impaired central insulin action in the
context of obesity-related IR. These mechanisms help to explain the association between
T2D and AD [67] and the correlation between central obesity and impaired cognitive
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function in the elderly [76]. The data from animal studies implicate hippocampal IR as a
mediator of cognitive dysfunction in patients with both T2D and AD [77]. To compound the
effects of IR on obesity-associated T2D, cardiovascular risk factors (including hypertension
and atherogenic dyslipidaemia) further contribute independently towards the development
of cognitive impairment [78].
In support of an important role for insulin in cognitive function, various studies
support the notion of insulin as a neuroprotector. In one study on normal rats, the intra-
hippocampal injection of insulin significantly improved spatial memory ability [79]. Fur-
thermore, the application of nasal insulin in a diabetic mouse model resulted in improved
decline in cognitive function related to DM, in addition to changes in molecular pathol-
ogy and brain morphology [46,80]. In another study, the use of the insulin sensitizer,
pioglitazone, in a rat T2D model improved learning and memory function [81]. There are
also data from human studies that suggest a beneficial effect of insulin administration on
cognitive function, including improved memory function in patients with AD following
insulin administration to maintain constant levels of glycaemia [82]. However, there are
limitations of such human-based studies with peripheral administration of insulin, due to
the confounding effects of the peripheral metabolic effects of insulin (including improved
glycaemic control in DM). This important confounder limits any firm conclusions regard-
ing the direct central effects of insulin on cognitive function in humans, with most of the
supporting evidence derived from animal-based studies, as outlined above.
5. Reversibility of IR with Lifestyle Interventions
Although IR plays a central role in the complex pathogenesis of metabolic dysfunction
and cognitive dysfunction in people who gain weight and develop obesity, the compelling
data support an important effect of lifestyle factors on insulin sensitivity. Undoubtedly,
some of the improvements in insulin sensitivity following the adoption of healthy lifestyle
factors stem from the attendant weight loss and reduction of excess adiposity. However,
unfortunately, the typical trajectory of weight change following lifestyle modification
emerges with early weight loss, a plateau at around six months and subsequent progressive
and insidious weight gain thereafter [9,10]. Nevertheless, despite the challenges associ-
ated with the long-term maintenance of body weight, the beneficial effects of improved
lifestyle on insulin sensitivity occur even independently of changes in body weight. The
current evidence promotes close attention to the optimisation of lifestyle in the effective
management of obesity-related IR, as a means of improving future cardiovascular risk
and overall wellbeing. In this section, we provide a concise overview of the effects of key
lifestyle factors on the reversibility of IR and discuss the main implications for the clinical
management of obesity.
Physical activity: Much evidence supports an important role for regular physical
activity and exercise in the optimisation of insulin sensitivity and the converse association
of sedentariness with IR [83]. Physical training potentiates the effects of physical exercise
on insulin sensitivity through the optimisation of glucose transport and metabolism [83].
Therefore, the degree of physical activity versus sedentariness represents an important
underlying determinant of the overall spectrum of insulin sensitivity within the population.
In a meta-analysis that included 17 studies on the effects of physical exercise on IR in
overweight and obese children and adolescents, compared with the control group, exercise
(especially aerobic training) associated with significant reductions in fasting serum insulin
levels and homeostasis model assessment of insulin resistance (HOMA-IR) [84]. Indeed,
even nonstrenuous physical exercise appears to influence IR. In a randomised trial of
women with T2D (n = 53) divided into exercise and control groups, it was shown that
an eight-week exercise program that consisted of stretching and walking activities three
times per week resulted in significant improvements in IR, including significant reductions
in plasma glucose and insulin levels [85]. Furthermore, in addition to the evidence for
the relatively short-term and immediate effects of physical activity on insulin sensitivity,
other data supports longer-term effects. In one large retrospective study on more than 6800
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Japanese adults aged between 40 and 79 years, it was shown that those who engaged in
regular physical exercise throughout their teenage years into their 30s and 40s reduced their
risk of IR (odds ratios (ORs) of 0.75 and 0.76 for men and women, respectively, following
adjustments for other variables) [86]. Furthermore, there was a linear trend between the
degree of regular physical exercise during younger years and the level of IR in middle and
older age [86].
Although much evidence supports an important role of the physical activity and
avoidance of sedentariness in the reduction of IR in both the short and longer terms, the
underlying mechanisms that mediate such effects remain incompletely understood. In one
study on skeletal muscle with comparisons between inherited IR and matched healthy
controls and between trained and sedentary subjects, there were 12 genes identified that
were associated with IR, in which the transcriptome profile reversed with exercise [87].
Furthermore, two IR-related genes (MSTN and IL32) were identified within muscle cells
from both young and old subjects, providing insight into possible mechanisms by which
exercise mediates metabolic benefits in humans with inherited IR [87]. However, more
research is required to provide further insight into the underlying mechanisms that mediate
effects of physical activity on insulin sensitivity.
Diet: Regarding the effects of dietary macronutrients on insulin sensitivity, some
of our most compelling evidence relates to dietary fibre intake [88–93]. Our own group
published the data from the highly phenotyped ProFiMet interventional study on 111
overweight adults with features of the metabolic syndrome, who were assigned randomly
to one of four isoenergetic diets, each with a duration of 18 weeks [94]. These diets
included high cereal fibre (HCF), high protein (HP), mixed high cereal fibre and protein
(Mix). For the 84 participants who completed the dietary intervention, insulin sensitivity
was significantly (25%) greater in the HCF group compared with those in the HP diet
group [94]. We hypothesized that the attenuated effects of HCF on insulin sensitivity at
18 weeks probably resulted from the reduced dietary adherence towards the end of the
trial [94].
Noninterventional observational studies corroborate the benefits of dietary fibre on
insulin sensitivity. In one study from Mexico on more than 200 adolescents, following
adjustments for age, sex, intake of saturated fatty acids and body fat percentage, those
with the greatest dietary intake of fibre had a lower OR of 0.34 (95% CI (confidence
interval): 0.13–0.93) and had an IR (defined by a HOMA-IR) of >2.97 [95]. Furthermore, a
systematic review and meta-analysis on the application of dietary fibre and whole grains
as a management strategy for patients with DM, a high-fibre diet associated with improved
insulin sensitivity, and other aspects of metabolic health (lipid profile, HbA1C, body weight
and C-reactive protein) [96]. However, despite these compelling data that support the
beneficial effects of dietary fibre intake on insulin sensitivity, there were relatively few
controlled studies (with a notable exception [93] that reported on the longer-term (>12
months) metabolic effects of dietary fibre intake [96]. This should be a focus for future
research, to provide further evidence to promote the widespread adoption of a high-fibre
diet within the populace [97].
The mechanism(s) by which dietary fibre mediates its metabolic benefits remains
incompletely understood and contentious. Within the existing literature, current dogma
implicates effects of dietary fibre on SCFAs. More relevant to soluble, fermentable fibre, at
least some of the metabolic benefits probably do occur via effects on the gut microbiome,
with subsequent release of SCFAs [97]. Through effects both locally within the ileum
and following absorption across the ileal wall into the bloodstream, SCFAs may in turn
influence the release of various gut hormones [98–103], adipokines [104], bile acids [105]
and amino acid metabolic signatures [106], each of which may contribute towards overall
insulin sensitivity. SCFAs may also reduce the leakiness of the gut wall itself, thereby
limiting the absorption of endotoxins and the subsequent inducement of a generalised
chronic low-grade inflammatory response that often associates with worsened IR [97].
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However, the mechanisms by which dietary fibre exerts its metabolic benefits are
likely to be more complicated than simply through effects on SCFAs. Dietary fibre gen-
erally consists of a mixture of both soluble and insoluble components. Interestingly, the
predominant metabolic benefits (including the optimisation of insulin sensitivity and the
associated reduced risk of the T2D development) appear to derive from the consumption
of insoluble cereal dietary fibres and whole grains [97,107–112]. Conversely, soluble fibres
appear to improve both overall lipid profile and the glycaemic index of carbohydrate-rich
foods [91,113,114]. As outlined, although the mediation of some beneficial metabolic effects
of soluble dietary fibre may occur through changes in SCFAs, interestingly, a high dietary
intake of soluble, fermentable fibres does not associate with a reduced risk of develop-
ing T2D, in contrast to the increased dietary intake of insoluble, cereal fibres and whole
grains [110]. The long-term studies in rodents have demonstrated similar data [115,116].
Therefore, an important role of SCFAs in conveying improved insulin sensitivity following
the intake of insoluble (at best only moderately fermentable) fibres remains controver-
sial [117]. Indeed, the relative lack of the fermentability of insoluble dietary fibre, despite
its clear beneficial effects on improving insulin sensitivity and risk for the development of
T2D, supports an underlying mediating mechanism alternate to that of SCFAs. Our own
group proposed an inhibitory effect of dietary insoluble fibre on the absorption of dietary
protein [94], subsequently corroborated by further reported data from numerous studies
in humans and rodents, including interventional and prospective cohort studies [110].
Therefore, rather than changes in SCFAs, a more convincing explanation for at least some of
the metabolically beneficial and protective effects (including improved insulin sensitivity)
of dietary insoluble fibre (such as cereals and whole grains) is through the impairment of
protein absorption.
Regarding the nonfibre effects of macronutrients on insulin sensitivity, there remains
some controversy in the current literature. In a recently reported review on the effects
of dietary modification on weight loss, no evidence supported any single dietary plan
(including food group, dietary pattern or nutrient) as being more efficacious for weight
loss than other options [118]. However, low-carbohydrate or low-glycaemic-index diets
are associated with greater improvements in both IR and lipid profile [119]. Therefore, to
optimise fully the dietary effects on insulin sensitivity, perhaps our best option is to ensure
the combination of a high-fibre and low-carbohydrate diet.
Sleep: Sleep forms an essential component of human physiology. Unfortunately, sleep
deprivation has become endemic in our modern society [120]. Sleep deprivation has far-
reaching implications that extend well beyond IR and metabolic dysfunction [121]. In recent
years, an abundance of data have emerged that provide compelling evidence to link sleep
deprivation with increased risk of IR, obesity and T2D [120,122,123]. Interestingly, limited
reported data implicate sleep fragmentation in the development of IR [124]. In a large study
on more than 1000 European participants, the data derived from the relationship between
insulin sensitivity and cardiovascular disease (EGIR-RISC) included self-reported sleep
duration. There was a U-shaped association between sleep duration and IR, confirming
an association of IR with extremes of sleep duration [125]. Furthermore, body mass index
(BMI) was an important mediator between sleep duration and IR [125].
Although incompletely understood, the factors that mediate IR in response to sleep de-
privation likely implicate central autonomic pathways, endocrine responses (e.g., changes
in the key appetite hormones ghrelin and leptin) and inflammatory status [120,122]. How-
ever, the data from rodent-based studies suggest that changes in the gut microbiota in
response to sleep deprivation may also mediate important effects on IR. In a study on
mice that were exposed to sleep fragmentation for four weeks, there was increased food
intake and reversible changes in the gut microbiota (including preferential growths of Lach-
nospiraceae and Ruminococcaceae and a reduction of Lactobacillaceae) [126]. Furthermore,
sleep-fragmented mice had WAT inflammation and worsened IR, hypothesized to result
from enhanced disruption to the colonic epithelial barrier [126]. Future studies should
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explore the effects of sleep duration on the human gut microbiota, as a potential novel
therapeutic target for improved insulin sensitivity.
6. Conclusions
Evidence-based conclusions: Obesity represents a global threat to health. A large
amount of the ramifications of obesity stem from its numerous indirect effects, including
adverse effects on socio-economic aspects (e.g., taking sick leave from work, unemployment
and reduced productivity and earnings), stigma (e.g., discrimination and social exclusion)
and overall mental health, wellbeing and quality of life. Furthermore, the direct effects
of obesity are substantial and include association with more than 50 obesity-related co-
morbidities [127]. There are variable underlying pathogeneses for these numerous co-
morbidities. These range from mechanical effects of obesity from pressure on weight-
bearing joints, restrictions of breathing and restrictions of the upper airways in obstructive
sleep apnoea to the effects of obesity-related societal views, prejudices and stigma on
the development of depression and other mental health problems, including adverse
impact on overall emotional wellbeing, self-esteem and general productivity [1]. However,
despite these variable pathogeneses, IR represents a common theme that interweaves many
of direct obesity-related co-morbidities, particularly relating to metabolic and cognitive
effects [128]. In this way, IR sits at crossroads between weight gain (excess adiposity) and
obesity and the metabolic and cognitive dysfunction that characterises and underlies many
of obesity-related co-morbidities (Table 1).
Table 1. IR at the crossroad of obesity with associated metabolic abnormalities and cognitive dysfunction: factors that
mediate effects of obesity on IR, the metabolic and cognitive sequelae of IR and the lifestyle reversibility of IR.
Factors that Mediate the
Effects of Obesity on IR Metabolic Sequelae of IR Cognitive Sequelae of IR Lifestyle Reversibility of IR
Chronic inflammation Hypertension Cognitive dysfunction Physical activity and avoidance ofsedentariness
Mitochondrial dysfunction Dyslipidaemia Learning deficiency Optimised dietary fibre intake
Gut microbiota dysbiosis Dysglycaemia Memory impairment Limited dietary carbohydrateintake
Adipose ECM remodelling Nonalcoholic fatty liver disease& polycystic ovary syndrome
Impaired hippocampal
synaptic plasticity
Optimised sleep sufficiency and
quality
Given the central role of IR as a key mediator in the deleterious effects of obesity, the
successful modification of IR forms an important therapeutic strategy. Although weight
loss associates with improved insulin sensitivity in the context of obesity, a key point is
that the effective and potentially chronic improvement of IR can occur simply through
the adoption of a healthy lifestyle. Of particular relevance to IR includes three pillars
of lifestyle: (i) regular engagement in physical activity and avoidance of sedentariness;
(ii) adoption of a healthy diet including high-fibre dietary intake; and (iii) improved
sleep quality and sufficiency with the avoidance of sleep deprivation and disruption.
Unfortunately, many of us in our modern-day world fail to achieve at least one of these
healthy lifestyle components. Although there is popular engagement in physical activities
in our leisure time, modern-day technology limits the need for many of us to engage
in physically demanding tasks, at least in our work. Our modern-day highly processed
and fibre-impoverished diets often stymie attempts at dietary modification [129]. Our
modern-day “24/7” instant-access culture with busy and stressful lifestyles, noisy and
light environments can have a negative impact on our sleep pattern. Furthermore, our
culture and society does not seem to value sleep in the way that it should [130]. Indeed,
as a pillar of a healthy lifestyle, sleep somehow often seems neglected from its other two
counterparts, diet and exercise.
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Public health recommendations: Although effective weight loss remains a key man-
agement strategy for obesity, the co-morbidities of obesity (mediated by IR) are also
modifiable through effective lifestyle modifications. This would require a multifaceted
approach in multiple settings (including schools) and address societal misconceptions
regarding the benefits of physical activity and the avoidance of sedentariness [131], opti-
mised dietary fibre intake [132] and the key principles of sleep hygiene and the importance
of regular sleep sufficiency [133]. Key stakeholders can also make a difference, including
food producers/companies and supermarkets/food retailers to optimise fibre contents of
highly processed foods [97] and town planners and local councils to ensure the facilita-
tion of pedestrian and cyclist transport [134]. Furthermore, cultural changes are required
regarding the adoption of healthy lifestyles [135], particularly the value and importance
of regular sleep sufficiency [133]. The effective population-wide implementation of these
lifestyle modifications would benefit substantially the health of the nation.
With the grim era of the Covid-19 pandemic considered as another paradigm at the
time of writing this review, it is easy to adopt a narrow-minded and struthious public
health perspective and focus on one virus/disease at the expense of all other long-term
health threats that affect our species. This is in no way to diminish the importance of the
current Covid-19 pandemic and the herculean efforts to control the spread of this new
virus, manage its sequelae and develop effective vaccines [136]. However, even in this
context, aside from the older age, obesity (and associated IR) represents a major risk factor
for both the susceptibility to and severity of the Covid-19 infection [137]. Therefore, the
implementation of the lifestyle factors outlined here is particularly apt and important in
the current era with the emergence of Covid-19 catalysing the urgency, with which we
must act at a national level to improve our future health. It is also worth remembering this
mantra for life: “when it is nobody’s responsibility, it is everybody’s responsibility”.
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